New data on three compounds from Basilea's anti-infectives portfolio presented at ICAAC
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG / New data on three compounds from Basilea's anti-infectives portfolio presented at ICAAC processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, September 16, 2010 - Data on the novel antibiotic compound
BAL30072, on ceftobiprole and isavuconazole were presented at the 50(th) annual
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in
Boston. The data on BAL30072 specifically demonstrate the high in-vitro activity
of the new monosulfactam antibiotic against multi-resistant Gram-negative
bacteria and elucidate structural elements involved in its unique antimicrobial
activity.
Multi-resistant Gram-negative bacteria are appearing with increasing frequency
in hospitals around the world causing an increase in mortality, particularly
when initial antibiotic therapy does not provide coverage of the causative
pathogen, and putting a significant economic burden on healthcare systems. The
local emergence of new antibiotic resistance mechanisms against almost all
available therapeutics will spread to a worldwide public health problem unless
new antibiotics active against multi-resistant bacteria are developed.
BAL30072 - a Trojan horse fighting resistance of Gram-negative bacteria
BAL30072 is a novel siderophore monosulfactam antibiotic that can act like a
"Trojan horse" by exploiting natural nutrient uptake systems to gain access to
its target. New in-vitro data reveal that a specific structural element of the
BAL30072 molecule, the siderophore side chain, contributes directly to its
antibacterial activity against clinically increasingly problematic
multi-resistant Gram-negative bacteria such as Pseudomonas spp. and Klebsiella
spp. (Poster F1?2132). Furthermore, there is new evidence that an accelerated
uptake of BAL30072, facilitated by the compound's siderophore side chain,
potentiates its in-vitro activity against Acinetobacter baumannii, a pathogen
which can cause severe pneumonia and infections of the urinary tract and
bloodstream (Poster F1-2133).
Basilea is preparing for moving BAL30072 into phase I clinical testing in Q4
2010.
+------------------------------------------------------------------------------+
|Posters on BAL30072 at ICAAC 2010 |
| |
|The Role of the Siderophore Moiety in the Activity of the Novel Monosulfactam |
|BAL30072. - M. G. P. PAGE, F. RICHALET, C. MÜLLER, B. HOFER, E. DESARBRE; |
|F1-2132 |
| |
|Enhanced Activity of the Siderophore Monosulfactam BAL30072 (BAL) against |
|Acinetobacter in Iron-Limited Conditions. - M. G. PAGE, C. MÜLLER, B. HOFER, |
|E. DESARBRE; F1-2133 |
| |
|Exploring Novel Inhibitors of FOX-4 Class C ?-Lactamase. - S. MALLO, C. |
|BETHEL, F. PEREZ-LLARENA, F. PRATI, E. CASELLI, M. PAGE, G. BOU, R. BONOMO; |
|F1-2134 |
| |
|CMY-33, A Novel Extended Spectrum Beta-Lactamase (ESBL) of the CMY-2 Family. -|
|M. TARACILA, A. ENDIMIANI, C. R. BETHEL, Y. DOI, M. G. P. PAGE, R. A. BONOMO; |
|C1-1961 |
| |
|For further information please visit www.icaac.org |
+------------------------------------------------------------------------------+
Ceftobiprole and isavuconazole - broad-spectrum antimicrobial activity for the
treatment of potentially life-threatening infections
A series of posters further adds to the wealth of existing in-vitro and clinical
data underscoring the broad-spectrum activity of the antibiotic ceftobiprole
against Gram-positive pathogens, including methicillin-resistant Staphylococcus
aureus (MRSA), and Gram-negative pathogens, including Pseudomonas spp. In
particular, ceftobiprole demonstrates bactericidal in-vitro activity against
clinical isolates of Enterococcus faecalis, unlike other cephalosporins (Poster
A1-1376). Enterococci belong to the most common pathogens involved in
hospital-associated infections and frequently cause bloodstream infections and
wound infections in hospitalized patients. Furthermore, Kim and co-workers
unveil in abstract E?2043 in-vitro results from the Asian Network for
Surveillance of Resistant Pathogens (ANSORP) study comprising major respiratory
isolates from hospital-acquired pneumonia (HAP) from 10 Asian countries. The
authors conclude that ceftobiprole could be an important therapeutic option for
HAP caused by resistant pathogens.
Isavuconazole, a novel broad-spectrum triazole in phase III clinical testing
against potentially life-threatening invasive fungal infections, showed potent
in-vitro activity against a large panel of recent clinical isolates of
Aspergillus spp. (Poster M-375).
+------------------------------------------------------------------------------+
|Posters on ceftobiprole at ICAAC 2010 |
| |
|Pharmacodynamic (PD) Activity of Ceftobiprole (Cefto) Compared to Vancomycin |
|(Vanco) vs. Enterococcus faecalis Using an In Vitro Model. - G. G. ZHANEL, N. |
|LAING, L. COX, E. ROSSNAGEL, D. VOTH, J. A. KARLOWSKY, D. J. HOBAN; A1-1376 |
| |
|Efficacy of Ceftobiprole (BPR) Alone and in Combination with Vancomycin (VAN) |
|in a Rat MRSA Infective Endocarditis (IE) Model. - J. FERNANDEZ, D. ABBANAT, |
|R. K. FLAMM, J. HASTINGS, A. M. BARRON, A. S. LYNCH; B-061 |
| |
|In Vivo Synergism of Ceftobiprole in Combination with Vancomycin against |
|Experimental Endocarditis Due to Vancomycin-Intermediate Staphylococcus |
|aureus. - J. VOUILLAMOZ, J. M. ENTENZA, T. R. VELOSO, M. GIDDEY, P. MOREILLON;|
|B-062 |
| |
|Characterization of ?-Lactamase Negative Ampicillin-Resistant (BLNAR) and |
|?-Lactamase Positive Amoxicillin-Clavulanate-Resistant (BLPACR) Haemophilus |
|influenzae. - T. A. DAVIES, A. E. STEVENSON, W. HE, G. J. NOEL, S. I. PELTON; |
|C2-117 |
| |
|In Vitro Activities of Ceftaroline and Ceftobiprole against Penicillin- and |
|Macrolide-Non-Susceptible Streptococcus pneumoniae (SPN)-CANWARD 2009. - A. K.|
|WIERZBOWSKI1, H. J. ADAM, J. KARLOWSKY, D. J. HOBAN, G. G. ZHANEL; E-818 |
| |
|Effects of Ceftobiprole and Comparators Alone and in Combination in an in |
|vitro Staphylococcal Biofilm Model. - D. ABBANAT, C. SANTORO, W. SHANG, E. |
|BAUM, S. CRESPO-CARBONE, A. S. LYNCH; E-1562 |
| |
|In Vitro Activities of Ceftobiprole and Doripenem against Major Bacterial |
|Isolates of Hospital-Acquired Pneumonia in Asian Countries: An ANSORP Study. -|
|S. KIM, J. SONG, D. CHUNG, M. LEE, K. KO, Ansorp Study Group; E-2043 |
| |
|Poster on isavuconazole at ICAAC 2010 |
| |
|Isavuconazole Wild-Type (WT) MIC Distributions and Epidemiological Cut-Off |
|Values (ECVs) for Clinical Isolates of Aspergillus spp. - T. PELÁEZ, A. |
|ESPINEL-INGROFF, B. GAMA, E. REIGADAS, J. GUINEA, L. ALCALÁ, P. MUÑOZ, E. |
|BOUZA; M-375 |
| |
|For further information please visit www.icaac.org |
+------------------------------------------------------------------------------+
About Basilea
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on
the SIX Swiss Exchange (SIX:BSLN). Its fully integrated research and development
operations are currently focused on antibiotics, antifungals and oncology drugs,
as well as on the development of dermatology drugs, targeting the medical
challenge of resistance and non-response to current treatment options in the
hospital and specialty care setting.
Basilea is currently marketing Toctino® (alitretinoin), the only approved
treatment for severe chronic hand eczema unresponsive to potent topical
corticosteroids, in Denmark, France, Germany, Switzerland and the United Kingdom
and has appointed distributors for Toctino® in other selected European markets,
Canada and Mexico. Furthermore, a phase III clinical program on alitretinoin for
the treatment of severe chronic hand eczema is ongoing in the U.S. The company
has entered into a global partnership with Astellas Pharma Inc. for its phase
III compound isavuconazole, a potential best-in-class azole antifungal, for the
treatment of life-threatening invasive fungal infections. Full rights to
ceftobiprole for the treatment of potentially life-threatening resistant
bacterial infections are being transferred back to Basilea from Cilag GmbH
International, a Johnson & Johnson company.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new information,
future events or otherwise.
For further information, please contact:
+-----------------------------+--------------------------------+
| Media Relations | Investor Relations |
+-----------------------------+--------------------------------+
| Adesh Kaul | Barbara Zink, Ph.D., MBA |
| Head Public Relations & | Head Corporate Development |
| Corporate Communications | |
| +41 61 606 1460 | +41 61 606 1233 |
| media_relations(at)basilea.com | investor_relations(at)basilea.com |
+-----------------------------+--------------------------------+
This press release can be downloaded from www.basilea.com
[HUG#1444708]
--- End of Message ---
Basilea Pharmaceutica AG
Grenzacherstrasse 487
P.O Box Basel Switzerland
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;
Press Release (PDF):
http://hugin.info/134390/R/1444708/388283.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 16.09.2010 - 07:15 Uhr
Sprache: Deutsch
News-ID 42597
Anzahl Zeichen: 0
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 518 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New data on three compounds from Basilea's anti-infectives portfolio presented at ICAAC"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
